Myriad Genetics, Inc. (MYGN): Price and Financial Metrics

Myriad Genetics, Inc. (MYGN): $15.45

0.06 (-0.39%)

POWR Rating

Component Grades








MYGN Price/Volume Stats

Current price $15.45 52-week high $24.21
Prev. close $15.51 52-week low $13.92
Day low $15.29 Volume 735,900
Day high $15.83 Avg. volume 568,172
50-day MA $17.81 Dividend yield N/A
200-day MA $20.08 Market Cap 1.27B

MYGN Stock Price Chart Interactive Chart >


  • MYGN scores best on the Value dimension, with a Value rank ahead of 66.14% of US stocks.
  • MYGN's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • MYGN ranks lowest in Momentum; there it ranks in the 5th percentile.

MYGN Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.41 for MYRIAD GENETICS INC; that's greater than it is for only 21.74% of US stocks.
  • With a year-over-year growth in debt of 102.38%, MYRIAD GENETICS INC's debt growth rate surpasses 89.88% of about US stocks.
  • Over the past twelve months, MYGN has reported earnings growth of 484.19%, putting it ahead of 96.77% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to MYRIAD GENETICS INC, a group of peers worth examining would be FNA, XGN, PLPC, INGN, and BSQR.
  • Visit MYGN's SEC page to see the company's official filings. To visit the company's web site, go to

MYGN Valuation Summary

  • MYGN's price/earnings ratio is -5.5; this is 120.6% lower than that of the median Healthcare stock.
  • MYGN's price/sales ratio has moved down 2.9 over the prior 243 months.

Below are key valuation metrics over time for MYGN.

Stock Date P/S P/B P/E EV/EBIT
MYGN 2023-09-22 1.9 1.8 -5.5 -5.6
MYGN 2023-09-21 2.0 1.9 -5.5 -5.6
MYGN 2023-09-20 2.0 1.9 -5.6 -5.7
MYGN 2023-09-19 2.0 1.9 -5.7 -5.8
MYGN 2023-09-18 2.0 1.9 -5.6 -5.7
MYGN 2023-09-15 1.9 1.8 -5.5 -5.6

MYGN Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -260.93%.
  • Its 5 year revenue growth rate is now at 0.46%.
  • Its 2 year cash and equivalents growth rate is now at 36.53%.
MYGN's revenue has moved down $152,000,000 over the prior 33 months.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 661.4 -108.5 -77.3
2022-06-30 672.3 -146 -17.6
2022-03-31 682.4 -100.1 -8.2
2021-12-31 690.6 18.2 -27.2
2021-09-30 684.4 13.7 -57.5
2021-06-30 662.3 -6.3 -97.3

MYGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MYGN has a Quality Grade of C, ranking ahead of 61.95% of graded US stocks.
  • MYGN's asset turnover comes in at 0.476 -- ranking 93rd of 681 Pharmaceutical Products stocks.
  • CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN.

The table below shows MYGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.476 0.705 -0.277
2021-03-31 0.404 0.685 -0.395
2020-12-31 0.390 0.680 -0.514
2020-09-30 0.407 0.698 -0.425
2020-06-30 0.424 0.709 -0.380
2020-03-31 0.493 0.737 -0.285

MYGN Price Target

For more insight on analysts targets of MYGN, see our MYGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.25 Average Broker Recommendation 2.11 (Hold)

Myriad Genetics, Inc. (MYGN) Company Bio

Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.

MYGN Latest News Stream

Event/Time News Detail
Loading, please wait...

MYGN Latest Social Stream

Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about MYRIAD GENETICS INC that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Is Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

Unpacking the Risks and Rewards of Investing in Myriad Genetics (MYGN)

Yahoo | September 29, 2023


A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and family health history are two misunderstood breast cancer risk factors.

Yahoo | September 28, 2023

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey revealing breast density and family health history are two misunderstood breast cancer risk factors. The Myriad Genetics Cancer Risk Survey found that nearly half (48%) of the women surveyed do not know what breast density is, and 50% are unsure if breast density has anything to do with breast cancer risk. Wo

Yahoo | September 28, 2023

Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up

Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina.

Yahoo | September 20, 2023

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera

Yahoo | September 19, 2023

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo N/A
3-mo -31.42%
6-mo N/A
1-year -25.04%
3-year 18.94%
5-year -64.96%
YTD 6.48%
2022 -47.43%
2021 39.57%
2020 -27.38%
2019 -6.33%
2018 -15.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!